ALT Altimmune Inc

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

• JMP Securities Life Sciences Conference in New York, NYTuesday, May 16, 2023Fireside chat at 9:00 am Eastern TimeThe session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

• Piper Sandler Spring Biopharma Symposium in Boston, MAThursday, May 18, 2023One-on-one meetings only

About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard EisenstadtChief Financial OfficerPhone: 240-654-1450reisenstadt@altimmune.com